Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial

BACKGROUND AND OBJECTIVE: IPX066 is a multiparticulate extended-release formulation of carbidopa–levodopa, designed to produce prolonged therapeutic levodopa plasma concentrations. This 9-month open-label extension study assessed its long-term safety and clinical utility in early and advanced Parkin...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, Cheryl H., Nausieda, Paul, Dzyak, Lyudmila, Spiegel, Joerg, Rudzinska, Monika, Silver, Dee E., Tsurkalenko, Elena S., Kell, Sherron, Hsu, Ann, Khanna, Sarita, Gupta, Suneel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555339/
https://www.ncbi.nlm.nih.gov/pubmed/25895021
http://dx.doi.org/10.1007/s40263-015-0242-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555339/
https://www.ncbi.nlm.nih.gov/pubmed/25895021
http://dx.doi.org/10.1007/s40263-015-0242-2

Ejemplares similares